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A significant proportion of prostatic adenocarcinomas show recurrent translocation 
leading to ERG expression. Previously we found that ERG+ cases have higher mi-
crovessel density than negative ones. One factor influencing angiogenesis in cancer 
is mast cells. The aim of the present study was to evaluate the relationship between 
microvessels, mast cells and ERG status.
Tissue microarrays prepared from 113 radical prostatectomy specimens were ana-
lyzed with immunohistochemistry for CD31, tryptase and chymase. Vascular profiles 
and tryptase-positive and chymase-positive cells were counted. 
The average number of tryptase-positive cells was 28.93/mm2 and chymase-posi-
tive cells 9.91/mm2. The average number of CD31+ vascular profiles was 352.66/
mm2. The average number of tryptase-positive cells was 26.35/mm2 for ERG– cases 
and 32.12/mm2 for ERG+ cases. The average number of chymase-positive cells was 
8.14/mm2 for ERG– cases and 12.06/mm2 for ERG+ cases. The average number 
of CD31+ vascular profiles was 321.34/mm2 for ERG– cases and 390.74/mm2 for 
ERG+ cases. The number of CD31+ vascular profiles was positively correlated with 
the number of tryptase-positive and chymase-positive cells (R = 0.26 and R = 0.20). 
In summary, we demonstrated an interrelationship between mast cells, microvascular 
density and ERG status in prostatic carcinoma. 
Key words: mast cell, chymase, tryptase, ERG, prostate cancer, microvessel den-
sity, CD31.
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Introduction
In the Western world prostatic carcinoma (PC) is 
the most frequent cancer in males [1, 2]. Its molecu-
lar pathogenesis is complex, yet a significant propor-
tion of cases bear recurrent translocation involving 
ETS family genes; this results in increased expression 
of ETS transcription factors, most frequently ERG, 
which may be easily detected by immunohistochemis-
try [3, 4]. In one of our previous studies, the frequen-
cy of ERG positivity in PC was 46%, which is similar 
to other European populations [5]. We found that 
ERG-positive PC have a higher number of microves-
sels [6]. Tumor vascularity is dependent on a number 
of factors; in some cases mast cells were shown to in-
fluence microvessel density [7, 8], while in others no 
such association was seen [9]. The aim of the study 
was to analyze the relationship between ERG expres-
sion, microvessel density and mast cell count.
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Material and methods
The material for the study consisted of unselect-
ed radical prostatectomy specimens from the files of 
the Pathology Department. All prostate specimens 
were dissected by the standard method, routine-
ly processed and completely embedded in paraffin. 
The slides were reviewed by a urologic pathologist. 
The cases were reclassified according to the 2015 re-
vised Gleason system and staged according to current 
TNM criteria [0, 11, 12]. Lymphovascular invasion 
and status of surgical margins were also reevaluated. 
From each case one representative section was cho-
sen. On the slide, the region of interest containing 
carcinoma infiltrate was marked, then its extent was 
copied to the surface of the paraffin block. For the tis-
sue microarray (TMA) construction a manual device 
(Histopathology Inc., Hungary) was used. From the 
region marked as cancer on each paraffin block, two 
2 mm cores were obtained and transferred into a re-
cipient block. The case numbers with respective loca-
tion in the TMA were noted on an Excel (Microsoft 
Inc., USA) spreadsheet. The upper-left corner of the 
TMA was left empty to allow proper orientation of 
the resulting slides. From the TMA paraffin blocks, 
2 mm sections were prepared and stained with hema-
toxylin-eosin (HE) and immunohistochemistry. HE 
slides were used to control the quality of tissue. Im-
munohistochemistry was done in the routine manual 
manner. Heating in citrate buffer for 30 minutes was 
used for antigen retrieval. For ERG staining, a rab-
bit monoclonal antibody (clone EPR3864), produced 
by Abcam was used in 1 : 200 dilution. Primary an-
ti-tryptase antibody (Leica Biosystems GmbH, Wet-
zlar, Germany) at 1 : 100 dilution and anti-chymase 
antibody (Abcam, Cambridge, UK) at 1 : 100 dilution 
were used. The Lab Vision detection system (Thermo 
Fisher Scientific, Waltham, USA) was used. 3-amino- 
9-ethylcarbazole was used as the chromogen. The 
slides were counterstained with Mayer’s hematoxylin 
(Thermo Fisher Scientific, Waltham, USA) and cover-
slipped. The results of the ERG staining were scored 
as positive when unequivocal nuclear staining was 
present; very faint nuclear as well as any cytoplasmic 
reaction was ignored, as previously reported [5]. The 
slides for tryptase (Fig. 1) and chymase (Fig. 2) were 
examined on an Olympus CH20 optical microscope 
equipped with a 40× lens; the entire TMA core was 
visually scanned, and the number of immunopositive 
cells and number of fields of view were recorded. The 
results were expressed as the number of positive cells 
per square millimeter. The data on microvessel den-
sity were derived from our previous work [6]. The 
person performing the counting was not aware of the 
ERG status or other data under study. The results 
were collected in an Excel spreadsheet containing the 
case numbers. Statistics were calculated with Statisti-
ca 10 (StatSoft Inc., USA). Student’s t test was used. 
The correlations were assessed by Spearman’s meth-
od. The significance level was set to 0.05.
Results
The study group consisted of 113 radical prosta-
tectomy specimens. The mean age of the patients was 
62.2 years (range 42 to 78, SD 6.40). None of the 
patients received androgen deprivation therapy.
Distribution of Gleason scores and grade groups is 
shown in Table I. Extraprostatic extension was seen 
in 69 cases (61.1%). pT stages are shown in Table II. 
In 1 case lymph node metastases were present. The 
surgical margins were positive in 50 cases (44.2%). 
Lymphovascular invasion was detected in 38 cases 
(33.6%). Reaction for ERG was negative in 62 cases 
(54.9%) and positive in 51 cases (45.1%).
Fig. 1. Tryptase-positive mast cells in prostatic carcinoma. 
Immunohistochemistry, original magnification 400× 
Fig. 2. Chymase-positive mast cells in prostatic carcinoma. 
Immunohistochemistry, original magnification 400×
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The average number of tryptase-positive cells 
was 28.93/mm2 (SD 17.06) and of chymase-posi-
tive cells 9.91/mm2 (SD 11.55). The average num-
ber of CD31+ vascular profiles was 352.66/mm2 
(SD 170.18). The average number of tryptase-posi-
tive cells was 26.35/mm2 (SD 13.90) for ERG– cases 
and 32.12/mm2 (SD 19.99) for ERG+ cases (Fig. 3). 
This difference was not statistically significant (p < 
0.08). The average number of chymase-positive cells 
was 8.14/mm2 (SD 8.81) for ERG– cases and 12.06/
mm2 (SD 13.98) for ERG+ cases (Fig. 4). This dif-
ference was not statistically significant (p < 0.08). 
The average number of CD31+ vascular profiles 
was 321.34/mm2 (SD 159.52) for ERG– cases and 
390.74/mm2 (SD 176.45) for ERG+ cases. This dif-
ference was statistically significant (p < 0.037). The 
number of CD31+ vascular profiles was positively 
correlated with the number of tryptase-positive and 
chymase-positive cells (R = 0.26, p < 0.01 and R = 
0.20, p < 0.05 respectively). The number of CD31+ 
vascular profiles showed some reverse correlation 
with grade group (R = –0.11 and R = –0.13, re-
spectively) yet this was not statistically significant. 
The cases without extraprostatic extension showed 
a somewhat higher number of tryptase-positive cells 
than cases extending out of the prostate (32.73/mm2 
versus 26.46/mm2) yet this was not statistically sig-
nificant. No relationship between number of mast 
cells and stage, lymph node status, surgical margins 
status or lymphovascular invasion was detected.
Discussion
Mast cells (MCs) are often disregarded because 
they constitute usually a minor population of cells in 
inflammatory infiltrate and they are difficult to ob-
serve without specific stains. However, the number of 
observations concerning their role in both chronic in-
flammation and cancer is increasing. They have been 
implicated in promotion of tumor growth, principal-
ly by their proangiogenic effect, as well as participa-
tion in antitumor immunity [13, 14, 15]. In the last 
years a number of studies concerning mast cells in the 
microenvironment of prostatic carcinoma have been 
published. The issue remains controversial, because 
cells with different phenotypes and location within 
different compartments may have contrasting effects 
on tumor growth [15]. 
Table I. Distribution of grades by modified Gleason score 
and corresponding ISUP grade groups
gleasOn n % grade grOup n %
6 = 3 + 3 47 41.6 1 47 41.6
7 = 3 + 4 41 36.3 2 41 36.3
7 = 4 + 3 13 11.5 3 13 11.5
8 = 4 + 4 3 2.7
4 6 5.38 = 3 + 5 2 1.8
8 = 5 + 3 1 0.9
9 = 4 + 5 4 3.5
5 6 5.3
9 = 5 + 4 2 1.8
Table II. Distribution of stages
n %
pT2a 7 6.2
pT2b 3 2.7
pT2c 34 30.1
pT3a 52 46.0
pT3b 15 13.3
pT4 2 1.8
Fig. 4. Tryptase-positive mast cells in ERG-negative and 
ERG-positive prostatic carcinoma. Central point is mean, 
box mean ± standard error, whisker mean ± 1.96* stan-
dard error
Fig. 3. Tryptase-positive mast cells in ERG-negative and 
ERG-positive prostatic carcinoma. Central point is mean, 
box mean ± standard error, whisker mean ± 1.96* stan-
dard error
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Aydin et al. [16] compared the number of mast 
cells in prostatic hyperplasia and carcinoma. They 
found a significantly higher number of MCs within 
the tumor, compared to hyperplasia, while where was 
no difference between hyperplasia and benign pros-
tatic tissue surrounding carcinoma. There was no as-
sociation between MC number and Gleason score in 
cancer cases. 
Stawerski et al. [17] found a significant correla-
tion between number of mast cells and microvessel 
density. This correlation was present both in cancer 
and nonneoplastic prostate. Both mast cell number 
and microvessel density were correlated with Glea-
son score, and to a lesser degree with PSA level. In 
our study we observed a similar relationship with 
microvessel MC density, while the relationship be-
tween MCs and tumor grade was inverse and very 
weak. The inverse correlation between Gleason score 
and MC density could be expected from other stud-
ies [18, 19], while others reported results similar to 
Stawerski et al. [20]. 
Some studies use traditional toluidine blue stain-
ing for MCs, which may be of limited sensitivity and 
specificity yet facilitates appreciation of the degran-
ulation status of MC [19]. Other studies ignore the 
phenotype of mast cells in the prostate, using trypt-
ase as the only marker, and others, such as Globa 
et al. [21], evaluated the phenotype of mast cells. 
They analyzed prostatic carcinoma in comparison 
to normal or hyperplastic prostate and found two 
populations of MCs, namely tryptase+/CD117+/
chymase– and tryptase–/chymase+/CD117+ in 
benign prostate, while in cancer cases intratumoral 
cells were tryptase+/chymase+/CD117+, and in 
the peritumoral areas three different populations of 
MCs, namely tryptase+/ chymase+/CD117–, trypt-
ase+/CD117+/chymase– and chymase+/CD117+/
tryptase–, were detected. In our study we used only 
tryptase and chymase stain, and analyzed only intra-
tumoral population of MCs.
Johansson et al. [22] found that mast cells have 
a stimulatory effect on tumor angiogenesis in PC. 
Forced degranulation of mast cells increases tumor 
growth in an experimental PC model parallel to in-
creased microvessel volume density, whereas stabiliza-
tion of mast cells inhibited both tumor growth and 
vessel formation. Importantly, these effects were not 
observed in tumor-cells-only in vitro models. It was 
hypothesized that the tumor inhibitory effect me-
diated by mast cell reduction may be obtained by 
imatinib, which opens the way to clinical application 
of mast cell research. Obviously, this is not the only 
mechanism whereby imatinib may act on cancer cells. 
One mechanism by which mast cells induce angiogen-
esis could be production of FGF-2, although FGF-2 
may be secreted by other cells, such as macrophages, 
fibroblasts and possibly epithelial cells. In human sub-
jects two contrasting effects of mast cell infiltrate were 
seen. The number of mast cells within nonneoplastic 
prostate was not correlated with microvessel density; 
nevertheless high mast cell number was a strong and 
independent predictor of poor prognosis. Conversely, 
the patients with a low intratumoral mast cell number 
fared significantly better; also this effect was indepen-
dent of other recognized prognostic factors. Castration 
therapy increased the number of peritumoral but not 
intratumoral mast cells.
Colombo et al. [18] suggested divergent effects of 
mast cells on prostate cancer depending on the de-
gree of differentiation of the tumor. The low grade 
cancers with clear-cut glandular differentiation were 
significantly more proliferative in the presence of 
mast cells and in animal models could in fact be mast 
cell dependent, while this effect was lost in poorly 
differentiated areas. High mast cell number could in-
deed be protective against appearance of neuroendo-
crine differentiation during progression of the tumor.
Pittoni et al. [19] in an animal model observed the 
number of MCs increasing in the sequence: normal → 
PIN → well-differentiated adenocarcinoma. Howev-
er, this decreased in poorly differentiated areas. In ar-
eas of well-differentiated adenocarcinoma MCs were 
also degranulated, indicating their functional role. 
The presence of MCs was correlated with the ability 
of tumor cells to produce CSF, the ligand of C-KIT 
receptor constitutively expressed by MCs. The pres-
ence of functional MCs was necessary for the growth 
of well-differentiated PC; this could be abolished 
by blockage of MC degranulation. In MC-deficient 
mice, tumor growth was inhibited and this inhibi-
tion was reversed by MC restoration. This MC de-
pendence could be explained by the inability of can-
cer cells to produce MMP9, which was produced and 
supplied by the MCs. The long term anti-MC treat-
ment in PC-prone TRAMP mice caused the appear-
ance of a rapidly growing tumor with neuroendocrine 
features. Similar tumors developed in bioengineered 
mice combining TRAMP and C-KIT-negative phe-
notypes.
Lu et al. [23] found that in vitro antiandrogenic 
agents recruit increased numbers of mast cells. They 
found higher numbers of mast cells in vivo in PC than 
in adjacent non-neoplastic prostate as well as in-
creased ability to recruit mast cells in vitro of prostate 
cancer cell lines compared to non-neoplastic prostate 
cell lines. Co-culture of stimulated mast cells with 
prostate cancer cells increased invasiveness of the lat-
ter. These effects could depend on downregulation of 
the AR pathway and finally de-suppression of MMP9. 
Mast cell/PC cell co-culture also resulted in increased 
numbers of tumor stem cells. AR pathway modula-
tion could lead to increased neuroendocrine differen-
tiation of PC cells [24]. Effects on the AR pathway 
and MMP9 were more pronounced in CD133+ than 
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in CD133– cells. In mice, adding MCs to injected PC 
cells increased the metastasis formation rate from 20 
to 70% of cases. Similarly to in vitro studies, MC sup-
plemented cases showed reduced AR and increased 
MMP9 expression [23]. 
Some papers have focused attention on the specific 
location of mast cells, notably intra- and peritumor-
al; analysis of these were not possible in the present 
study because of the TMA experiments’ design, sim-
ilar to e.g. Fleischmann et al. [25]. Nonomura et al. 
[20] analyzed mast cells in prostatic biopsy material. 
They found MCs only in the immediate vicinity of 
cancer infiltrate. They found a significant correlation 
of MC number with the stage of the tumor as well 
as Gleason grade. Also, the patients with biochemi-
cal relapse had higher MC counts compared with the 
rest of the study group, and survival of patients with 
a low MC number was significantly higher than the 
high MC group. There was however no correlation 
between MC number and preoperative PSA level or 
patients’ age. The prognostic effects of MCs were ob-
served both in radically treated (surgical radiation) 
patients and in patients on androgen deprivation 
only and were present also in multivariate analysis. 
Xie et al. [26] observed significantly higher re-
cruitment of MC by PC cell lines in comparison to 
normal prostatic cell lines. Also, after MC recruit-
ment, cancer cell lines became resistant to the che-
motherapeutic agent docetaxel; this resistance was 
due to decreased apoptosis caused by activating p38/
p53/p21 signaling, and could be reversed by its inhi-
bition. Similar results could be obtained by mice in 
vivo models. Also, PC cell lines co-cultured with MC 
showed higher resistance to radiation and less radia-
tion-induced DNA damage. The increased radiore-
sistance was due to increase in ATM phosphorylation. 
Fleischmann et al. [25] analyzed a large cohort of 
PC patients for MC status using TMAs. They found 
an inverse correlation between the number of mast 
cells and PSA level, Gleason score and tumor stage. 
The patients with the highest mast cell count also 
had better survival; this effect disappeared however 
if the Gleason score was taken into account. It is of 
note that the method of assessment (TMA) allows 
only counting of intratumoral mast cells, whose 
prognostic significance is different from peritumoral 
mast cells. 
In summary, we demonstrated an interrelationship 
between mast cells, microvascular density and ERG 
status in prostatic carcinoma. These results need to 
be confirmed in larger material, and the nature of the 
link elucidated. It will also be important to determine 
whether and how this interacts with the prognosis.
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